Etentamig Biosimilar Bispecific Antibody (CD3 × BCMA) for Research

Cat No.: GMP-Bios-INN-1192

Anti-CD3E therapeutic antibody (Pre-made Etentamig biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Etentamig (development code ABBV-383) is a bispecific antibody targeting CD3 and BCMA (TNFRSF17). It is developed by TeneoBio and Abbvie for multiple myeloma, amyloid light-chain amyloidosis. It is in Phase III clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1192-1mg 1mg
GMP-Bios-INN-1192-10mg 10mg
GMP-Bios-INN-1192-100mg 100mg
GMP-Bios-INN-1192-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Etentamig biosimilar, Bispecific mAb, Anti-CD3E;TNFRSF17/CD269/BCMA/TNFRSF13A Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody
INN Name Etentamig
Target CD3E;TNFRSF17/CD269/BCMA/TNFRSF13A
Format Bispecific mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G4
VD LC Kappa
Highest_Clin_Trial (Jan '20) Phase-III
Est. Status Active
100% SI Structure None;None
99% SI Structure None;None
95-98% SI Structure None;None
Year Proposed 2024
Year Recommended 2024
Companies TeneoBio;Abbvie
Conditions Approved na
Conditions Active Multiple myeloma;Amyloid light-chain amyloidosis
Conditions Discontinued na
Production na
Development Tech Transgenic rat